Work

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3010

Authors: Kartik Sehgal, Jesus Corral Jaime, Steven Francis Powell, Cesar Augusto Perez, Elisa Fontana, Ed Kingsley, Federico Longo Munoz, Sarina A. Piha-Paul, Rachel E. Sanborn, Jonathan Hayman, Francesca Toffalorio, Tianhua Wang, Wyatt Chafin, Solange Peters

Institutions: Dana-Farber Cancer Institute, Hospital Universitario de Jerez, Sanford Health, Sarah Cannon Research Institute, Comprehensive Cancer Centers of Nevada, Hospital Universitario Ramón y Cajal, The University of Texas MD Anderson Cancer Center, Providence Portland Medical Center, Pfizer (United States), Pfizer (Italy), Centre Hospitalier Universitaire Vaudois

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815041

Cites:

Cited by: 8

Related to: 10